Zhejiang Medicine Co., Ltd. (SHA:600216)
China
· Delayed Price · Currency is CNY 17.64
-0.74 (-4.03%)
Mar 9, 2026, 3:00 PM CST
Zhejiang Medicine Revenue
Zhejiang Medicine had revenue of 2.37B CNY in the quarter ending September 30, 2025, a decrease of -12.37%. This brings the company's revenue in the last twelve months to 8.96B, down -0.81% year-over-year. In the year 2024, Zhejiang Medicine had annual revenue of 9.38B with 20.29% growth.
Revenue (ttm)
8.96B
Revenue Growth
-0.81%
P/S Ratio
1.87
Revenue / Employee
1.54M
Employees
5,815
Market Cap
16.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.38B | 1.58B | 20.29% |
| Dec 31, 2023 | 7.79B | -321.66M | -3.96% |
| Dec 31, 2022 | 8.12B | -1.01B | -11.10% |
| Dec 31, 2021 | 9.13B | 1.80B | 24.60% |
| Dec 31, 2020 | 7.33B | 283.01M | 4.02% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tonghua Dongbao Pharmaceutical | 2.74B |
| Shandong Buchang Pharmaceuticals | 10.96B |
| Fujian Cosunter Pharmaceutical | 430.98M |
| Betta Pharmaceuticals | 3.26B |
| Walvax Biotechnology | 2.40B |
| China Resources Double-Crane Pharmaceutical | 10.95B |
| Shenzhen Kangtai Biological Products | 2.70B |
| Nanjing King-Friend Biochemical Pharmaceutical | 3.76B |